. 2013 Jan 15;2013:878237. doi: 10.1155/2013/878237

Table 2.

Followup information from individuals with TDR associated with ARV resistance.

ID^a	HIV exposure^b	Age^c/gender^d	ART regimen^e	CD4+ T cells		Viral load		Time to last VL/CD4 test^j	Resistance mutations (CPR)^k	Resistance mutations (IAS)^l	Subtype^m
				(cells/mm³)		(Log₁₀)		Time to last VL/CD4 test^j	Resistance mutations (CPR)^k
				Before ART^f	Last test^g	Before ART^h	Last testⁱ
BR08SP441	MSM	25/M	TDF/3TC/EFV	312	311	4.40	4.78	N.A		E138A	B
BR09SP005	MSM	41/M	AZT/3TC/LPV	388	1025	4.77	<1.70	13 months		E138A	B
BR09CA065	MSM	37/M	TDF/3TC/EFV	248	641	4.43	<1.70	8 months		V82I	B
BR09CA067	MSM	38/M	AZT/3TC/EFV	244	817	4.58	<1.70	31 months		V82I	B
BR09CA071	MSM	29/M	—	487	562	3.58	2.61	—	K103N	K103N	B
BR09CA075	WSM	66/F	AZT/3TC/EFV	224	378	5.70	<1.70	18 months		E138A	B
BR09CA091	MSM	30/M	TDF/3TC/LPV/r	260	384	4.94	<1.70	26 months	K103N	K103N	B
BR09CA097	WSM	40/F	—	567	567	4.18	4.18	—	G190A	G190A	B
BR09CA175	MSM	29/M	AZT/3TC/ATV/r	283	164	3.76	3.58	No supression	K103N	K103N	B
BR09CA190	WSM	32/F	AZT/3TC/EFV	207	609	4.47	<1.70	37 months		E138A	B
BR09CA192	MSM	29/M	—	751	686	3.74	4.25	—	K103N	K103N	B
BR09CA194	IDU+MSM	34/M	N.A.	230	230	—	<1.70	N.A.		Q58E	B
BR09CA210	MSM	22/M	—	741	636	5.19	4.90	—	M41L, T215E	M41L	B
BR09CA262	IGN	29/F	N.A.	217	209	5.45	5.24	—		V82I/E138A	C
BR09CA264	MSM	39/M	AZT/3TC/EFV	243	629	4.78	<1.70	37 months		V82I	B
BR09CA271	MSM	29/M	TDF/3TC/EFV	197	557	4.50	<1.70	26 months	M41L	M41L	B
BR09CA296	MSM	26/M	TDF/3TC/LPV/r	221	723	3.95	<1.70	29 months	K103N	K103N	B
BR09CA298	MSW	26/M	—	731	668	4.00	4.65	—	M230L	M230L	B
BR09CA300	MSM	21/M	—	1062	729	3.29	3.20	—		V82I	B
BR09SP310	MSM	27/M	TDF/3TC/RAL	108	955	5.55	<1.70	15 months		E138A	B
BR09CA343	MSM	34/M	AZT/3TC/EFV	335	388	4.41	<1.70	35 months		E138A	B
BR09CA344	WSM	39/F	—	381	454	3.81	4.42	—	K101P, K103S	K101P, K103S	B
BR09CA355	WSM	53/F	TDF/3TC/EFV	318	787	3.52	<1.70	27 months	L90M	L90M	B
BR09CA369	MSW	58/M	TDF/3TC/EFV	348	348	4.76	—	N.A		E138A	BF
BR09SP588	MSM	33/M	—	517	441	4.49	4.07	—	M46I, L90M/K101P, G190A	M46I, Q58E, L90M/K101P, G190A	B
BR09SP003	pARV+MSM	41/M	TDF/3TC/DRV/r/RAL	312	490	4.86	<1.70	3 months	M46I, G73S, I84V, L90M/M41L, V75M, F77L, T215D, Y188L	M46I, I54V, I84V, L90M/M41L, F77L, Y188L	B
BR09CA078	pARV+WSM	40/F	AZT/3TC/EFV	297	492	3.57	<1.70	14 months		A72V	B
BR09CA095	pARV+MSM	32/M	—	631	658	2.68	3.07	—	K103N, L90M	K103N, L90M	B
BR09CA187	pARV+WSM	25/F	—	656	592	3.93	4.24	—		V82I	B
BR09CA280	pARV	28/M	—	632	395	3.61	4.19	—	K103N	K103N	B
BR09CA372	pARV+MSM	29/M	TDF/3TC/ATV/r	273	774	4.73	<1.70	37 months	K103N	K103N	B
BR09CA197	pARV+WSM	47/F	—	N.A.	N.A.	N.A.	N.A.	—	T215S, I85V		B
BR09SP253	pARV+WSM	47/F	—	1142	1334	2.06	2.70			V82I	B

^aSamples ID (BR from Brazil, 09 for year of collection, and CA or SP for clinical site and samples number).

^bExposure as MSM men that refers to sex with other men, WSM for women that refers to sex with men, IDU for intravenous drug use, and pARV for patients referring to sex with one or more partners using antiretroviral therapy.

^cAge in years, ^dgender as M for male, and F for female.

^eART treatment as first regimen or no treatment.

^fCD4+ T cells prior to treatment start (pre-ART) and ^glast CD4 available (bold for CD4 values higher than pre-ART, when ARV was taken);

^hViral load prior to ART (before ART) and ⁱlast VL available. (bold for undetectable viral copies/mL, <1.70 log₁₀, when ARV was taken).

^jTime since treatment initiation until last CD4/VL determination in months.

^k,lResistance mutations observed (Stanford CPR and 2011 IAS list).

^mViral subtype at pol region.

N.A. for data not available.